| Name | Title | Contact Details |
|---|
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.
At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife
Dendreon is a biotechnology company with a singular mission: to harness the power of the body`s immune system to safely improve and extend the lives of people battling cancer. Dendreon`s PROVENGE® (sipuleucel-T), which was approved by the U.S. Food and Drug Administration in April 2010, is the only cellular immunotherapy cancer treatment available. Dendreon is working to expand the application of its technology to discover, develop, manufacture and market additional product candidates for a variety of cancers in the future. Dendreon headquarters are in in Seal Beach, California.